Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Wells J.; Glassman A.; Ayala Allison R.; Jampol L.; Aiello L. P.; Antoszyk A.; Arnold-Bush Bambi; Baker C.; Bressler N.; Browning David J.; Elman M.; Ferris Frederick L.; Friedman Scott M.; Melia M.; Pieramici D.; Sun Jennifer K.; Beck R. W.

doi:10.1056/nejmoa1414264

← Today's brief

Study

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Wells J. et al. · The New England journal of medicine · Thursday, January 1, 2015

Read original

Funding Not reported

Source

Wells J. et al.. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England journal of medicine. Thursday, January 1, 2015.
doi:10.1056/nejmoa1414264

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.